Every Form 4 that Tempest Therapeutics Inc (TPST) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow TPST and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TPST filings page.
Tempest Therapeutics CEO-linked entity buys stock and warrants. Factor Bioscience Inc. acquired 231,482 shares of Tempest Therapeutics common stock and warrants to purchase 462,964 additional shares under a Securities Purchase Agreement dated March 20, 2026. The combined purchase price was $2.16 for each share plus an accompanying warrant.
The Series A and Series B Warrants each cover 231,482 underlying shares at an exercise price of $2.16 per share. Both warrant series become exercisable only after stockholder approval; Series A Warrants then run for five years, and Series B Warrants for twenty-four months. Reporting person Matthew Angel, Tempest’s CEO and President, is the majority stockholder and Chairman of Factor and exercises voting and investment power over Factor’s holdings.
Tempest Therapeutics director John D. Yee received a grant of stock options covering 25,000 shares of common stock. The options have an exercise price of $1.27 per share and expire on June 4, 2036. This is a compensation-related award, not an open-market purchase.
According to the terms, one-third of the options vest on the first anniversary of the June 4, 2026 grant date, with the remaining two-thirds vesting in equal monthly installments over the following two years, conditioned on his continued service. After this grant, Yee holds stock options for 25,000 shares directly.
Tempest Therapeutics director Richey William Drake received a grant of stock options for 25,000 shares of Common Stock. The options have an exercise price of $1.27 per share and expire on June 4, 2036. They vest over three years, with one-third on the first anniversary and the rest in equal monthly installments, contingent on continued service. Following this grant, he holds 25,000 options directly.
Tempest Therapeutics, Inc. reported that Corporate Controller Justin Trojanowski received a grant of employee stock options for 22,000 shares of common stock. The options have an exercise price of $1.64 per share and expire on March 30, 2036.
According to the vesting terms, 25% of the options will vest on March 31, 2027, with the remaining options vesting in 36 equal monthly installments thereafter, contingent on his continued service. Following this grant, his reported holdings in these options total 22,000 derivative securities, all held directly.
Tempest Therapeutics, Inc. reported that Chief Financial Officer Nicholas Maestas received a grant of employee stock options covering 140,000 shares of common stock at an exercise price of $1.64 per share. These options expire on March 30, 2036 and are held as a direct ownership position.
According to the vesting terms, 25% of the total shares will vest on March 31, 2027, with the remaining shares vesting in 36 equal monthly installments thereafter, contingent on Maestas’s continued service. Following this grant, he holds 140,000 options in this award.
Tempest Therapeutics director and CEO Matthew Angel reported an indirect open-market purchase of 231,482 shares of Common Stock at $2.16 per share. The shares are held by Factor Bioscience Inc., where he serves as chief executive officer and chairman, and he disclaims beneficial ownership except for his proportionate pecuniary interest.
Following this transaction, Factor Bioscience Inc. holds 231,482 shares indirectly attributed to Angel, while he also directly holds 4,837,070 shares of Tempest Therapeutics Common Stock. A footnote explains that the reported holdings reflect pro rata share distributions by Erigen LLC that changed only the form of his ownership.
Tempest Therapeutics, Inc. CEO, President and director Matthew Angel, also a 10% owner, reported a grant of employee stock options on February 4, 2026. He received options to purchase 269,621 shares of common stock at an exercise price of $2.38 per share, expiring on February 3, 2036.
According to the vesting schedule, 25% of the underlying shares will vest on February 4, 2027, with the remaining shares vesting in 36 equal monthly installments thereafter, subject to his continued service. Following this award, he beneficially owns 269,621 derivative securities directly.
Tempest Therapeutics director Ronit Simantov received a stock option grant for 1,230 shares on January 27, 2026. The option has an exercise price of $2.94 per share and was granted at no cost. It will vest in full on the earlier of January 27, 2027, or the company’s 2026 annual stockholder meeting, provided Simantov continues serving through that date.
Tempest Therapeutics director Nichol Geoffrey received a grant of stock options on January 27, 2026. The award covers 1,230 options to buy Tempest common stock at an exercise price of $2.94 per share, all held directly.
These options will vest in full on the earlier of January 27, 2027, or the day of Tempest’s 2026 annual stockholder meeting, if Geoffrey continues to serve through that date. Following this grant, he beneficially owns 1,230 derivative securities linked to Tempest shares.
Tempest Therapeutics director receives stock option grant. Director Michael Raab was granted a stock option to purchase 1,230 shares of Tempest Therapeutics, Inc. common stock at an exercise price of $2.94 per share on January 27, 2026.
The option vests in full on the earlier of January 27, 2027 or the date of the company’s 2026 annual stockholder meeting, contingent on his continuous service through that date. Following this grant, he beneficially owns 1,230 derivative securities directly, with the option expiring on January 26, 2036.
Tempest Therapeutics director Christine A. Pellizzari reported a new stock option grant. On January 27, 2026, she was awarded an option to buy 1,230 shares of Tempest Therapeutics common stock at an exercise price of $2.94 per share, held directly.
The option vests in full on the earlier of January 27, 2027 or the day of Tempest Therapeutics' 2026 annual stockholder meeting, as long as she continues serving through that date. The option expires on January 26, 2036, and represents 1,230 derivative securities beneficially owned following the grant.